Kane Biotech Inc. (TSXV: KNE)
Canada
· Delayed Price · Currency is CAD 0.110
-0.005 (-4.35%)
Nov 21, 2024, 9:43 AM EST
Kane Biotech Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.76 | 0.15 | 0.16 | 1.61 | 1.34 | 1.69 | Upgrade
|
| Revenue Growth (YoY) | - | -4.95% | -90.25% | 19.84% | -20.78% | 234.51% | Upgrade
|
| Cost of Revenue | 0.3 | 0.04 | 0.04 | 1.04 | 0.81 | 1.08 | Upgrade
|
| Gross Profit | 0.46 | 0.11 | 0.11 | 0.57 | 0.53 | 0.61 | Upgrade
|
| Selling, General & Admin | 3.36 | 2.41 | 2.53 | 4.07 | 3.43 | 2.66 | Upgrade
|
| Research & Development | 1.62 | 1.05 | 1.04 | 1.31 | 1.29 | 1.33 | Upgrade
|
| Operating Expenses | 4.97 | 3.46 | 3.57 | 5.39 | 4.71 | 3.99 | Upgrade
|
| Operating Income | -4.51 | -3.35 | -3.46 | -4.82 | -4.18 | -3.38 | Upgrade
|
| Interest Expense | -0.97 | -1.22 | -0.82 | -0.42 | -0.12 | -0.14 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 0.02 | 0.12 | 0.04 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.01 | 0 | -0.02 | 0 | 0 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -5.47 | -4.56 | -4.28 | -5.11 | -4.27 | -3.52 | Upgrade
|
| Asset Writedown | -0.01 | -0.01 | - | -0.07 | -0.04 | -0.21 | Upgrade
|
| Legal Settlements | - | - | - | - | - | 2.67 | Upgrade
|
| Other Unusual Items | - | 0 | 0.25 | 0.32 | 0.46 | 0.11 | Upgrade
|
| Pretax Income | -5.48 | -4.56 | -4.02 | -4.85 | -3.85 | -0.96 | Upgrade
|
| Earnings From Continuing Operations | -5.48 | -4.56 | -4.02 | -4.85 | -3.85 | -0.96 | Upgrade
|
| Earnings From Discontinued Operations | 10.3 | -0.47 | 0.13 | - | - | - | Upgrade
|
| Net Income to Company | 4.83 | -5.03 | -3.89 | -4.85 | -3.85 | -0.96 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 0.25 | 0.13 | - | Upgrade
|
| Net Income | 4.83 | -5.03 | -3.89 | -4.6 | -3.72 | -0.96 | Upgrade
|
| Net Income to Common | 4.83 | -5.03 | -3.89 | -4.6 | -3.72 | -0.96 | Upgrade
|
| Shares Outstanding (Basic) | 131 | 127 | 121 | 113 | 109 | 82 | Upgrade
|
| Shares Outstanding (Diluted) | 144 | 127 | 121 | 113 | 109 | 82 | Upgrade
|
| Shares Change (YoY) | 14.62% | 5.32% | 7.20% | 3.67% | 31.97% | 2.73% | Upgrade
|
| EPS (Basic) | 0.04 | -0.04 | -0.03 | -0.04 | -0.03 | -0.01 | Upgrade
|
| EPS (Diluted) | 0.04 | -0.04 | -0.03 | -0.04 | -0.03 | -0.01 | Upgrade
|
| Free Cash Flow | -5.82 | -3.23 | -3.05 | -2.48 | -3.97 | -0.91 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -0.03 | -0.03 | -0.02 | -0.04 | -0.01 | Upgrade
|
| Gross Margin | 60.54% | 73.48% | 71.48% | 35.36% | 39.27% | 36.01% | Upgrade
|
| Operating Margin | -596.18% | -2248.93% | -2206.05% | -299.63% | -311.93% | -199.40% | Upgrade
|
| Profit Margin | 637.45% | -3379.05% | -2481.86% | -286.39% | -277.04% | -56.70% | Upgrade
|
| Free Cash Flow Margin | -769.03% | -2168.64% | -1947.70% | -153.99% | -295.64% | -53.69% | Upgrade
|
| EBITDA | -4.47 | -3.23 | -3.3 | -4.73 | -4.12 | -3.32 | Upgrade
|
| EBITDA Margin | - | - | - | -294.36% | - | -196.21% | Upgrade
|
| D&A For EBITDA | 0.04 | 0.12 | 0.16 | 0.08 | 0.07 | 0.05 | Upgrade
|
| EBIT | -4.51 | -3.35 | -3.46 | -4.82 | -4.18 | -3.38 | Upgrade
|
| EBIT Margin | - | - | - | -299.63% | - | -199.40% | Upgrade
|
| Revenue as Reported | 0.76 | 0.15 | 0.16 | 1.61 | 1.34 | 1.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.